Gilead Sciences (GILD) Net Income (2009 - 2026)
Gilead Sciences' (GILD) quarterly Net Income came in at $2.0 billion in Q1 2026, up 53.69% YoY from $1.3 billion in Q1 2025, and down 20.06% on a QoQ basis from $2.5 billion in Q4 2025.
Gilead Sciences (GILD) Net Income (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Net Income data on file, last reported at $2.0 billion in Q1 2026.
- Quarterly Net Income rose 53.69% year-over-year to $2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 billion (up 60.3% YoY) and the FY2025 annual result came in at $8.5 billion, up 1676.62% from the prior year.
- Net Income eased to $2.0 billion in Q1 2026, from $2.5 billion in the prior quarter.
- In the past five years, Net Income ranged from a high of $3.1 billion in Q3 2025 to a low of -$4.2 billion in Q1 2024.
- A 5-year average of $1.3 billion and a median of $1.6 billion in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2023 — Net Income jumped 8100.0% — and 2024, when it slumped 523.88%.
- Tracing GILD's Net Income over 5 years: stood at $1.6 billion in 2022, then dropped by 13.29% to $1.4 billion in 2023, then advanced by 25.85% to $1.8 billion in 2024, then soared by 41.86% to $2.5 billion in 2025, then dropped by 20.06% to $2.0 billion in 2026.
- The last three Net Income figures came in at $2.0 billion (Q1 2026), $2.5 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -238.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 17.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.50 Bn |
| Mar 31, 2026 | 2.02 Bn |
| Dec 31, 2025 | 2.53 Bn |
| Sep 30, 2025 | 3.05 Bn |
| Jun 30, 2025 | 1.96 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.78 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | -4.17 Bn |
| Dec 31, 2023 | 1.42 Bn |
| Sep 30, 2023 | 2.17 Bn |
| Jun 30, 2023 | 1.04 Bn |
| Mar 31, 2023 | 984.00 Mn |
| Dec 31, 2022 | 1.63 Bn |
| Sep 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 12.00 Mn |
| Dec 31, 2021 | 376.00 Mn |
| Sep 30, 2021 | 2.59 Bn |